number is estimated to increase to 50 million people by 2020.

NEI benefits children born with eye diseases and vision loss, as well as older citizens and everyone else that fits in between. NEI actively works to predict, prevent, and preempt aging eye disease and visual impairment thereby enabling more productive lives and reducing vision costs.

The National Eye Institute is the world leader in basic research with the National Institutes of Health's Human Genome Project to translate discoveries of genes related to eye disease and vision impairment which compromises one-quarter of genes, discovered to date, into diagnostic and treatment modalities.

The NEI has been a leader in collaborative research with so many private funding entities such as the human gene therapy trial with the Foundation Fighting Blindness, or this lead organization known as FFB, for individuals with Leber congenital amaurosis, a rapid retinal degeneration that blinds infants in their first year of life. This trial has demonstrated measurable visual improvement even with initial safety trials.

I am a big supporter of the Foundation Fighting Blindness, and the work that they have done in the past continues to carry out in our daily lives. This resolution recognizes the 40 years of service from the National Eye Institute and commends them for their leadership while supporting their mission to prevent blindness and save and restore vision.

Additionally, this resolution designates 2010 through 2020 as the "Decade of Vision" to maintain awareness in the next decade of public health challenges associated with vision impairment and eye disease, as well as to emphasize the need for prevention and early detection, access to treatment, and rehabilitation.

Lastly, we commend the National Alliance for Eye and Vision Research for its efforts to expand awareness of the incidence and economic burden of eye diseases through this Decade of Vision initiative.

Mr. Speaker, I am very proud of supporting not only this 40th anniversary but also to say that the United States Congress has what I believe is a realistic opportunity to work with the National Institutes of Health to make sure that we continue to push the envelope for people who are in this country and around the world who are counting on research and development to cure blindness during this Decade of Vision. I encourage all of my colleagues to vote in favor of this resolution.

I thank the gentlewoman from Wisconsin for her concentrated and special support of blindness issues. I look forward to working with her.

I yield back the balance of my time. Ms. BALDWIN. Mr. Speaker, I would now like to yield 3 minutes to a fellow member of the Energy and Commerce Committee and a champion of vision issues, Mr. GREEN of Texas.

Mr. GENE GREEN of Texas. I would like to thank my colleague, who is a diligent and hardworking member of our Energy and Commerce Committee, for sponsoring H.R. 366, celebrating the Decade of Vision and the National Eye Alliance's 40th anniversary.

As co-Chair of the Congressional Vision Caucus with a particular interest in vision health, I strongly support the National Eye Institute, which serves as the lead NIH institute that manages our Nation's commitment to save and restore vision.

NEI research has contributed to the development of several critical therapies and interventions that are helping to slow the progression of vision impairment. In some cases, these therapies are helping to restore sight for individuals who may otherwise have lost their vision. Treatments for diabetic retinopathy that were developed by NEI researchers save our health care system more than \$1.6 billion annually. Other NEI-funded research is resulting in treatments and therapies that are slowing the progression of vision impairment; in some cases, vision loss is even restored.

Starting next year, the first wave of the 78 million baby boomers will begin turning 65 years old, an age of elevated risk for aging eye disease. Coupled with the disproportionate incidences of eye disease in the African American and Hispanic populations and the increased incidence of diabetic eye disease, the NEI will be challenged more than ever to fund basic and clinical research that results in treatment and therapies.

As demonstrated by its past history, I am confident that the NEI will rise to this challenge, and, of course, we in Congress must work to ensure that it is adequately funded so that it can continue its research that benefits the health—and vision health—of all Americans.

Ms. BALDWIN. Mr. Speaker, I want to close by recognizing just a few of the champions of eye health and the warriors against eye disease from the district that I have the privilege of representing. And I know, like my coauthor, Congressman Sessions, we were drawn to this issue because of pioneering things that are happening in each of our respective districts.

Dr. Paul Kaufman is a leading eye researcher at the University of Wisconsin, Madison, and a major partner of the National Eye Institute. And I want to commend and recognize his groundbreaking research.

Also, a technology called BrainPort is being developed in my district by a company called Wicab with the support of National Eye Institute funding, and this technology is helping the blind to find new ways to process visual information. These sort-of breakthroughs are so exciting and really go back to the importance of celebrating the accomplishments to date and the future potential through the National Eye Institute with our support.

Again, I commend my colleagues support of this resolution.

I yield back the balance of my time. The SPEAKER pro tempore. The question is on the motion offered by the gentlewoman from Wisconsin (Ms. BALDWIN) that the House suspend the rules and agree to the resolution, H. Res 366.

The question was taken.

The SPEAKER pro tempore. In the opinion of the Chair, two-thirds being in the affirmative, the ayes have it.

Ms. BALDWIN. Mr. Speaker, on that I demand the yeas and nays.

The yeas and nays were ordered.

The SPEAKER pro tempore. Pursuant to clause 8 of rule XX and the Chair's prior announcement, further proceedings on this motion will be postponed.

ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, proceedings will resume on motions to suspend the rules previously postponed. Votes will be taken in the following order:

H.R. 2470, by the yeas and nays;

H.R. 780, by the yeas and nays;

H.R. 2247, by the yeas and nays;

H.R. 403, de novo.

The first electronic vote will be conducted as a 15-minute vote. Remaining electronic votes will be conducted as 5-minute votes.

LIEUTENANT COMMANDER ROY H. BOEHM POST OFFICE BUILDING

The SPEAKER pro tempore. The unfinished business is the vote on the motion to suspend the rules and pass the bill, H.R. 2470, on which the yeas and nays were ordered.

The Clerk read the title of the bill.

The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Massachusetts (Mr. Lynch) that the House suspend the rules and pass the bill, H.R. 2470.

This will be a 15-minute vote.

The vote was taken by electronic device, and there were—yeas 417, nays 0, not voting 16, as follows:

[Roll No. 340] YEAS-417

Bishop (GA) Abercrombie Bishop (NY) Ackerman Aderholt Bishop (UT) Adler (NJ) Blackburn Akin Blumenauer Altmire Blunt Andrews Boccieri Arcuri Boehner Bono Mack Austria Baca Boozman Boren Bachmann Bachus Boswell Baird Boucher Baldwin Boustany Barrett (SC) Boyd Brady (PA) Barrow Bartlett Brady (TX Barton (TX) Braley (IA) Bean Bright Becerra Broun (GA) Berman Brown (SC) Brown, Corrine Berry Biggert Brown-Waite, Bilbray Ginny Buchanan Bilirakis

Burgess Burton (IN) Butterfield Buver Calvert Camp Campbell Cantor Cao Capito Capps Capuano Cardoza Carnahan Carney Carson (IN) Carter Cassidy Castle Castor (FL) Chaffetz Chandler Childers Clarke

Clay

H6846	
Cleaver	Hoekstra
Clyburn Coble	Holden Holt
Coffman (CO)	Honda
Cohen Cole	Hunter Inglis
Conaway	Inslee
Conyers	Israel Issa
Cooper Costa	Jackson (IL)
Courtney	Jackson-Lee
Crenshaw Crowley	(TX) Jenkins
Cuellar	Johnson (GA)
Culberson Cummings	Johnson (IL) Johnson, E. B.
Dahlkemper	Johnson, Sam
Davis (AL) Davis (CA)	Jones Jordan (OH)
Davis (IL)	Kagen
Davis (KY) Davis (TN)	Kanjorski Kaptur
Deal (GA)	Kildee
DeFazio DeGette	Kilpatrick (MI) Kilroy
Delahunt	Kind
DeLauro Dent	King (IA) King (NY)
Diaz-Balart, L.	Kingston
Diaz-Balart, M. Dicks	Kirk Kirkpatrick (AZ)
Dingell	Kissell
Doggett Donnelly (IN)	Klein (FL) Kline (MN)
Doyle	Kosmas
Dreier Driehaus	Kratovil Kucinich
Duncan	Lamborn
Edwards (MD) Edwards (TX)	Lance Langevin
Ehlers	Larsen (WA)
Ellison Ellsworth	Latham LaTourette
Emerson	Latta
Engel Eshoo	Lee (CA) Lee (NY)
Etheridge	Levin
Fallin Farr	Lewis (CA) Linder
Fattah	Lipinski
Filner Flake	LoBiondo Loebsack
Fleming	Lofgren, Zoe
Forbes Fortenberry	Lowey Lucas
Foster Foxx	Luetkemeyer Luján
Frank (MA)	Lungren, Daniel
Franks (AZ) Frelinghuysen	E. Lynch
Fudge	Mack
Gallegly Garrett (NJ)	Maffei Maloney
Gerlach	Manzullo
Giffords Gingrey (GA)	Marchant Markey (CO)
Gohmert	Markey (MA)
Gonzalez Goodlatte	Marshall Massa
Gordon (TN)	Matheson
Granger Graves	Matsui McCarthy (CA)
Grayson	McCarthy (NY)
Green, Al Green, Gene	McCaul McClintock
Griffith	McCollum
Grijalva Guthrie	McCotter McDermott
Gutierrez	McGovern
Hall (NY) Hall (TX)	McHenry McHugh
Halvorson	McIntyre
Hare Harman	McKeon McMahon
Harper Hastings (FL)	McMorris Rodgers
Hastings (WA)	McNerney
Heinrich Heller	Meek (FL) Meeks (NY)
Hensarling	Melancon
Herger Herseth Sandlin	Mica Michaud
Higgins	Miller (FL)
Hill Himes	Miller (MI) Miller (NC)
Hinchey Hinojosa	Miller, Gary Miller, George
Hirono	Minnick
Hodes	Mitchell

	Mollohan
	Moore (KS)
	Moore (WI) Moran (KS)
	Moran (VA)
	Murphy (CT)
	Murphy (NY)
	Murphy, Patrick Murphy, Tim
	Murtha
	Myrick
	Nadler (NY)
	Napolitano
	Neal (MA) Neugebauer
	Nunes
	Nye
	Oberstar
	Obey Olson
	Olver
	Ortiz
	Pallone
	Pascrell
	Pastor (AZ) Paul
	Paulsen
	Payne
	Pence
	Perlmutter
)	Perriello Peters
	Peterson
	Petri
	Pingree (ME)
	Pitts
	Platts Poe (TX)
	Polis (CO)
	Pomeroy
	Posey
	Price (GA)
	Price (NC) Quigley
	Radanovich
	Rahall
	Rangel
	Rehberg
	Reichert Reyes
	Richardson
	Rodriguez
	Roe (TN)
	Rogers (AL) Rogers (KY)
	Rogers (MI)
	Rohrabacher
	Rooney
	Ros-Lehtinen
	Roskam Ross
	Rothman (NJ)
	Roybal-Allard
	Royce
	Ruppersberger Rush
	Ryan (OH)
	Ryan (WI)
	Salazar
	Sanchez, Loretta Sarbanes
	Scalise
	Schakowsky
	Schauer
	Schiff Schmidt
	Schock
	Schrader
	Schwartz
	Scott (GA)
	Scott (VA) Sensenbrenner
	Serrano
	Sessions
	Sestak
	Shaq-Porter
	Shea-Porter Sherman
	Shimkus
	Shuler
	Shuster
	Simpson Sires
	Skelton
	Slaughter
	Smith (NE)
	Smith (N.I)

Smith (NJ)

Smith (TX) Smith (WA)

Mollohan

Thornberry Snyder Wasserman Souder Schultz Tiahrt Space Tiberi Watson Speier Watt Tierney Waxman Spratt Titus Stark Weiner Tonko Stearns Welch Towns Westmoreland Stupak Tsongas Sutton Wexler Turner Whitfield Tanner Upton Tauscher Wilson (SC) Van Hollen Taylor Wittman Velázquez Wolf Teague Visclosky Terry Woolsey Walden Thompson (CA) Wıı Walz Thompson (MS) Yarmuth Thompson (PA) Wamp Young (AK) NOT VOTING-16

Sánchez, Linda Alexander Kennedy Larson (CT) Berkley Sullivan Bonner Lewis (GA) Connolly (VA) Waters Lummis Wilson (OH) Costello Putnam Hoyer Young (FL)

□ 1347

Mr. FOSTER changed his vote from "nay" to "yea.

So (two-thirds being in the affirmative) the rules were suspended and the bill was passed.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

STUDENT INTERNET SAFETY ACT OF 2009

The SPEAKER pro tempore. The unfinished business is the vote on the motion to suspend the rules and pass the bill, H.R. 780, as amended, on which the yeas and nays were ordered.

The Clerk read the title of the bill.

The SPEAKER pro tempore. The question is on the motion offered by the gentleman from the Northern Mariana Islands (Mr. Sablan) that the House suspend the rules and pass the bill, H.R. 780, as amended.

This will be a 5-minute vote.

The vote was taken by electronic device, and there were—yeas 416, nays 0, not voting 17, as follows:

[Roll No. 341]

YEAS-416 Boehner Abercrombie Carnahan Bono Mack Ackerman Carnev Carson (IN) Aderholt Boozman Adler (NJ) Boren Carter Boswell Akin Cassidy Altmire Boucher Castle Castor (FL) Andrews Boustany Chaffetz Bovd Arcuri Brady (PA) Austria Chandler Brady (TX) Braley (IA) Ba.ca. Childers Bachmann Clarke Bachus Bright Clay Broun (GA) Baird Cleaver Barrett (SC) Brown (SC) Clyburn Brown, Corrine Brown-Waite, Barrow Coble Coffman (CO) Bartlett Barton (TX) Ginny Cohen Bean Buchanan Cole Conaway Becerra Burgess Burton (IN) Berman Conyers Berry Butterfield Cooper Biggert Buver Costa Bilbray Calvert Courtney Camp Campbell Bilirakis Crenshaw Bishop (GA) Crowley Bishop (NY) Canton Cuellar Bishop (UT) Cao Capito Culberson Cummings Blackburn Blumenauer Capps Dahlkemper Blunt Capuano Davis (AL) Boccieri Cardoza Davis (CA)

Davis (TN) Deal (GA) DeFazio DeGette Delahunt DeLauro Dent Diaz-Balart, L. Diaz-Balart, M. Dicks Dingell Doggett Donnelly (IN) Doyle Dreier Driehaus Duncan Edwards (MD) Edwards (TX) Ehlers Ellison Ellsworth Emerson Engel Eshoo Etheridge Fallin Farr Fattah Filner Flake Fleming Fortenberry Foster Foxx Frank (MA) Franks (AZ) Frelinghuysen Fudge Gallegly Garrett (NJ) Gerlach Giffords Gingrey (GA) Gohmert Gonzalez Goodlatte Gordon (TN) Granger Graves Grayson Green, Al Green, Gene Griffith Grijalva Guthrie Gutierrez Hall (NY) Hall (TX) Halvorson Hare Harman Harper Hastings (FL) Hastings (WA) Heinrich Heller Hensarling Herger Herseth Sandlin Higgins Hill Himes Hinchey Hinojosa Hirono Hodes Hoekstra Holden Holt Honda Hunter Inglis Inslee Israel Jackson (IL) Jackson-Lee (TX) Jenkins Johnson (GA) Johnson (IL) Johnson, E. B. Johnson, Sam Jones Jordan (OH)

Davis (IL)

Davis (KY

Kagen Kanjorski Olson Olver Kaptur Ortiz Kildee Kilpatrick (MI) Kilroy Kind King (IA) King (NY) Kingston Kirk Kirkpatrick (AZ) Kissell Klein (FL) Kline (MN) Kosmas Kratovil Kucinich Lamborn Lance Langevin Larsen (WA) Latham LaTourette Latta Lee (CA) Lee (NY) Levin Lewis (CA) Linder Lipinski LoBiondo Loebsack Lofgren, Zoe Lowey Lucas Luetkemever Luján Lummis Lungren, Daniel Lynch Mack Maffei Maloney Manzullo Marchant Markey (CO) Markey (MA) Marshall Matheson Matsui McCarthy (CA) McCarthy (NY) McCaul McClintock McCollum McCotter McDermott McGovern McHenry McHugh McIntvre McKeon McMahon McMorris Rodgers McNerney Meek (FL) Meeks (NY) Melancon Mica Michaud Miller (FL) Miller (MI) Miller (NC) Miller, Gary Miller, George Minnick Mitchell Mollohan Moore (KS) Moore (WI) Moran (KS) Moran (VA) Murphy (CT) Murphy (NY) Murphy, Patrick Murphy, Tim Murtha Myrick Nadler (NY) Napolitano Neal (MA) Neugebauer

Nye Oberstar

Pallone Pascrell Pastor (AZ) Paul Paulsen Payne Pence Perlmutter Perriello Peters Peterson Petri Pingree (ME) Pitts Platts Polis (CO) Pomeroy Posey Price (GA) Price (NC) Putnam Quigley Radanovich Rahall Rangel Rehberg Reichert Reyes Richardson Rodriguez Rogers (AL) Rogers (KY) Rogers (MI) Rohrabacher Rooney Ros-Lehtinen Roskam Ross Rothman (N.I) Roybal-Allard Ruppersberger Rush Ryan (OH) Ryan (WI) Salazar Sanchez, Loretta Sarbanes Scalise Schakowsky Schauer Schiff Schmidt Schock Schrader Schwartz Scott (GA) Scott (VA) Sensenbrenner Serrano Sessions Sestak Shadegg Shea-Porter Sherman Shimkus Shuler Shuster Simpson Sires Skelton Slaughter Smith (NE) Smith (NJ) Smith (TX) Smith (WA) Snyder Souder Space Speier Spratt Stark Stearns Stupak Sutton Tanner Tauscher Taylor Teague Terry Thompson (CA) Thompson (MS) Thompson (PA) Thornberry Tiahrt